our products

Med Aditus Pharmaceuticals, Inc. has performed a rigorous analysis of pharmaceutical products for our launch into the Kenya and East Africa marketplaces.

Med Aditus Pharmaceuticals, Inc. plans to focus our initial launch of pharmaceutical products on the following categories to meet the needs in the Kenya and East Africa marketplaces.

Medications for noncommunicable diseases (NCDs)

Cardiovascular diseases and diabetes are quickly becoming a leading cause of death in sub-Saharan Africa.

The rising burden of noncommunicable diseases will exert pressure on treatment and care services. In the African region, the number of people living with diabetes, for example, is expected to reach 47 million by 2045 up from 19 million in 2019.

— WHO release

NCDs are set to overtake communicable, maternal, neonatal, and nutritional diseases as the leading cause of mortality in sub-Saharan Africa by 2030.

— The Lancet Global Health

Medications targeted to specifically address drug administration problems in the pediatric populations

According to the United Nations, Africa has the youngest population in the world.

In sub-Saharan Africa, 70 percent of the population is under 30 years of age.

— UN release

“Sub-Saharan Africa has the highest child (under 5) mortality rate in the world. One in 13 children die before reaching age 5 years.”

— The Lancet Global Health

Around 50 percent of the oral drugs in the World Health Organization (WHO)’s 7th list of Essential Medicines for Children (2019) are not formulated as age-appropriate products.

— MDPI

Biologics Products

The number of new cancer cases is expected to rise by 70% over the next two decades.

— Penn State report

“Between 2020 and 2040, cancer incidence and deaths are forecasted to rise fastest in Africa compared to other world regions.”

— WHO release

According to the World Health Organization’s International Agency for Research on Cancer recently released, the percentage of new cancer cases in 2050 will increase by more than 75 percent. In Africa alone, that percentage edges closer to 140 percent – 139.4 percent to exact."

— WHO report

These categories are just the beginning of Med Aditus Pharmaceuticals Inc.’s impact on the region. We plan to continuously explore opportunities to manufacture medicines to treat neglected tropical diseases (NTDs) and infectious disease. We are also in discussion to establish the capability to manufacture Biologics formulations.
Stay tuned.

our products

Med Aditus Pharmaceuticals, Inc. has performed a rigorous analysis of pharmaceutical products for our launch into the Kenya and East Africa marketplaces.

Medications for noncommunicable diseases (NCDs)

Medications targeted to specifically address drug administration problems in the pediatric populations

Biologics Products

Interested in becoming a strategic partner?